Citadel Advisors’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-147,500
| Closed | -$7.62M | – | 16022 |
|
|
2022
Q3 | $7.62M | Sell |
147,500
-16,300
| -10% | -$674K | ﹤0.01% | 3166 |
|
|
2022
Q2 | $4.06M | Sell |
163,800
-11,900
| -7% | -$262K | ﹤0.01% | 4184 |
|
|
2022
Q1 | $4.41M | Sell |
175,700
-244,400
| -58% | -$6.87M | ﹤0.01% | 4426 |
|
|
2021
Q4 | $15.3M | Sell |
420,100
-166,300
| -28% | -$5.84M | ﹤0.01% | 2387 |
|
|
2021
Q3 | $10M | Buy |
586,400
+320,100
| +120% | +$4.99M | ﹤0.01% | 3074 |
|
|
2021
Q2 | $3.57M | Buy |
266,300
+239,200
| +883% | +$5.89M | ﹤0.01% | 5205 |
|
|
2021
Q1 | $1.39M | Sell |
27,100
-10,200
| -27% | -$614K | ﹤0.01% | 7305 |
|
|
2020
Q4 | $2.31M | Buy |
37,300
+5,300
| +17% | +$303K | ﹤0.01% | 5063 |
|
|
2020
Q3 | $1.75M | Sell |
32,000
-33,400
| -51% | -$1.8M | ﹤0.01% | 4974 |
|
|
2020
Q2 | $3.76M | Buy |
65,400
+25,500
| +64% | +$1.39M | ﹤0.01% | 3493 |
|
|
2020
Q1 | $1.6M | Sell |
39,900
-13,200
| -25% | -$561K | ﹤0.01% | 4507 |
|
|
2019
Q4 | $2.1M | Sell |
53,100
-18,500
| -26% | -$325K | ﹤0.01% | 4344 |
|
|
2019
Q3 | $485K | Buy |
71,600
+53,500
| +296% | +$402K | ﹤0.01% | 6809 |
|
|
2019
Q2 | $168K | Sell |
18,100
-11,900
| -40% | -$138K | ﹤0.01% | 8302 |
|
|
2019
Q1 | $417K | Buy |
+30,000
| New | +$343K | ﹤0.01% | 7086 |
|
|
2018
Q1 | – | Sell |
-27,800
| Closed | -$165K | – | 8973 |
|
|
2017
Q4 | $165K | Buy |
27,800
+1,000
| +4% | +$6.86K | ﹤0.01% | 7230 |
|
|
2017
Q3 | $199K | Buy |
+26,800
| New | +$223K | ﹤0.01% | 6700 |
|
|
2016
Q1 | – | Sell |
-300
| Closed | -$2K | – | 8326 |
|
|
2015
Q4 | $2K | Buy |
+300
| New | +$2.12K | ﹤0.01% | 8588 |
|
|
2014
Q3 | – | Sell |
-4,400
| Closed | -$26K | – | 8512 |
|
|
2014
Q2 | $26K | Buy |
+4,400
| New | +$24.7K | ﹤0.01% | 7170 |
|
Other funds holding CCXI
Citadel Advisors's CCXI Position: Q4 2022 in Review
Citadel Advisors sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 112,981 shares — an estimated $5.84M sold.
Citadel Advisors first reported a position in CCXI in Q2 2014 and held it in 27 quarters. The position peaked at $43.6M in Q2 2020. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Citadel Advisors reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Citadel Advisors sold 112,981 ChemoCentryx, Inc. shares in Q4 2022, an estimated $5.84M.
- Citadel Advisors first reported a position in ChemoCentryx, Inc. in Q2 2014 and held it in 27 quarters.
- Citadel Advisors's ChemoCentryx, Inc. position peaked at $43.6M in Q2 2020.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.